Monsalve 2017 Abstract MITOEAGLE Barcelona: Difference between revisions
No edit summary |
Nirschl Lisa (talk | contribs) No edit summary Β |
||
Line 2: | Line 2: | ||
|title=[[File:MITOEAGLE-representation.jpg|left|60px|link=http://www.mitoglobal.org/index.php/MITOEAGLE|COST Action MITOEAGLE]] | |title=[[File:MITOEAGLE-representation.jpg|left|60px|link=http://www.mitoglobal.org/index.php/MITOEAGLE|COST Action MITOEAGLE]] | ||
Mitochondrial biogenesis in PMBC: potential biomarkers. | Mitochondrial biogenesis in PMBC: potential biomarkers. | ||
|info=[[ | |info=[[MitoEAGLE]] | ||
|authors=Fabregat-Andres O, Ridocci-Soriano F,Β Berenguer-Jofresa A, Corbi-Pascual M, Valle-Munoz A, Barrabes JA, Estornell-Erill J, Monsalve M | |authors=Fabregat-Andres O, Ridocci-Soriano F,Β Berenguer-Jofresa A, Corbi-Pascual M, Valle-Munoz A, Barrabes JA, Estornell-Erill J, Monsalve M | ||
|year=2017 | |year=2017 | ||
|event= | |event=MitoEAGLE Barcelona 2017 | ||
|abstract=[[Image:MITOEAGLE-logo.jpg|left|100px|link=http://www.mitoglobal.org/index.php/MITOEAGLE|COST Action MITOEAGLE]] | |abstract=[[Image:MITOEAGLE-logo.jpg|left|100px|link=http://www.mitoglobal.org/index.php/MITOEAGLE|COST Action MITOEAGLE]] | ||
Peroxisome proliferator activated receptor g co-activator 1a (PGC-1a) is a master on antioxidant systems. It is induced by ischemia and reperfusion (IR) and has been shown to prevent cardiac remodeling in mice. PGC-1a can be detected in blood samples of ST-segment elevation acute myocardial infarction (STEMI) patients. This study tested the predictive value of PGC-1a for cardiac healing and adverse ventricular remodeling (AVR) after STEMI. | Peroxisome proliferator activated receptor g co-activator 1a (PGC-1a) is a master on antioxidant systems. It is induced by ischemia and reperfusion (IR) and has been shown to prevent cardiac remodeling in mice. PGC-1a can be detected in blood samples of ST-segment elevation acute myocardial infarction (STEMI) patients. This study tested the predictive value of PGC-1a for cardiac healing and adverse ventricular remodeling (AVR) after STEMI. |
Latest revision as of 14:35, 12 January 2018
Mitochondrial biogenesis in PMBC: potential biomarkers. |
Link: MitoEAGLE
Fabregat-Andres O, Ridocci-Soriano F, Berenguer-Jofresa A, Corbi-Pascual M, Valle-Munoz A, Barrabes JA, Estornell-Erill J, Monsalve M (2017)
Event: MitoEAGLE Barcelona 2017
Peroxisome proliferator activated receptor g co-activator 1a (PGC-1a) is a master on antioxidant systems. It is induced by ischemia and reperfusion (IR) and has been shown to prevent cardiac remodeling in mice. PGC-1a can be detected in blood samples of ST-segment elevation acute myocardial infarction (STEMI) patients. This study tested the predictive value of PGC-1a for cardiac healing and adverse ventricular remodeling (AVR) after STEMI.
We prospectively studied 31 patients with a first anterior STEMI successfully reperfused. We analyzed PGC-1a mRNA in blood samples on admission and 72 h later, and tested its correlation with the extent of initial myocardial damage and cardiac volume and function at 6 months. Myocardial edema and necrosis were assessed during the first week by cardiac magnetic resonance (CMR). A second CMR examination was performed at 6 months to evaluate scar burden and AVR, defined as an increase over 10% in left ventricular end-diastolic volume (LVEDV).
PGC-1a induction is associated with larger edemas and higher risk of AVR. Patients with high basal PGC-1a levels have larger areas of initial salvaged myocardium (SM) and SM at 6 months. In the absence of microvascular obstruction (MVO) and with high basal PGC-1a, the risk of AVR is lower than in the presence of MVO with low basal PGC-1a.
Baseline expression and lack of induction of PGC-1a are associated with a reduced incidence of AVR after STEMI.
β’ Bioblast editor: Kandolf G
Labels: MiParea: mt-Biogenesis;mt-density, mt-Medicine, Patients, Pharmacology;toxicology
Stress:Ischemia-reperfusion
Tissue;cell: Blood cells
Event: A4
PMBCs
Affiliations
- Consorcio Hospital General Univ Valencia, Inst Investigaciones BiomΓ©dicas βAlberto Solsβ (CSIC), Madrid; Spain.